News

News2019-07-22T02:46:50+00:00

REGiMMUNE Appoints a new board member

REGiMMUNE Corporation announced today that it has appointed Mr. Kohtaro Toda as a board member. He is currently an investment manager of Japan Asia Investment Co., Ltd. (JAIC), a Japanese venture capital firm with $1 billion under management. The addition of this new management position reflects the company’s continued progress into a clinical stage company, [...]

March 23rd, 2012|

REGiMMUNE Initiates Phase I/II Clinical Trial for GvHD and Raises 5 Million Dollars in Series C to Fund Trial

Tokyo, Japan – January 31, 2012 (US time)– REGiMMUNE Corporation said today that it has begun a Phase I/II study of its proprietary compound RGI-2001 for Graft versus Host Disease (GvHD) associated with hematopoietic stem cell transplantation. The safety and efficacy study will enroll approximately 50 bone marrow or peripheral blood stem cell transplantation leukemia [...]

February 1st, 2012|

reVax patent has been granted

Basis patent for the target specific tolerance induction by GalCer liposome, reVax technology, has been granted Tokyo, JAPAN–(Nov 28, 2011) – REGiMMUNE Corp. (“Company”) announces that the Japanese Patent Office has granted a patent, containing claims for a target specific tolerance induction technology, which we named reVax technology. The issued patent covers the GalCer liposome [...]

November 28th, 2011|

Publication of GvHD paper

REGiMMUNE Corp. Announces Publication of preclinical GvHD data Tokyo, JAPAN–(Nov 22, 2010) – REGiMMUNE Corp. (“Company”) is pleased to announce the acceptance and publication of the paper entitled “Pharmacological Expansion of Donor-derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute GvHD Lethality without Abrogating GvL in Murine Models.” by the Biology of Blood and Marrow Transplantation(in [...]

November 22nd, 2010|

REGiMMUNE Presents New ToleroVax Data at the 2010 American Transplant Congress

REGiMMUNE Presents New ToleroVax Data at the 2010 American Transplant Congress San Diego, CA – May 4, 2010 – REGiMMUNE Corporation said today that data from a preclinical study showed an enhanced immune suppression when ToleroVax (RGI-2001), its lead product candidate for the prevention of acute Graft-versus-Host Disease (GvHD), is combined with anti-thymocyte globulin (ATG). [...]

April 30th, 2010|

Entered into a License Agreement with RIKEN

Tokyo, Japan –Sep. 1, 2006 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced that it has entered into a license agreement with RIKEN. Under the agreement, an exclusive right to market/sublicense pharmaceutical products based on RIKEN’s immune regulating technology is granted to REGiMMUNE from RIKEN. For Information Contact: Yuko Amizaki, Director, Corporate Planning REGiMMUNE. [...]

March 31st, 2010|

“REGiMMUNE to file IND of its Tolerance Inducing therapy” : An article is on Nikkei Business Paper today

KRN7000, a synthetic derivative of alpha-galactosylceramide, is a small molecule that potently activates natural killer T (NKT) cells. RGI-2001 is a proprietary liposomal formulation of KRN7000. RGI-2001 has shown to induce antigen-specific immune suppression by inducing regulatory T cells (Tregs). Tregs are believed to play a central role in inducing and maintaining immune tolerance. RGI-2001 [...]

August 28th, 2009|

Astellas and REGiMMUNE to Collaborate on New Vaccine Technology

Tokyo, Japan and Mountain View, CA – July 22, 2009 – REGiMMUNE Corporation today announced that Astellas Pharma Inc. and REGiMMUNE have entered into a collaboration agreement to jointly research and develop a novel vaccine-platform technology. The partnership will combine Astellas’ broad range of capabilities in screening and developing natural source-derived compounds with REGiMMUNE’s immune liposome [...]

July 22nd, 2009|

REGiMMUNE Presented Enhanced Efficacy Data in Preclinical Transplantation Models at the 2009 American Transplant Congress

Boston, MA – June 1, 2009 – REGiMMUNE Corporation today announced that its lead product candidate RGI-2001, in combination with a low-dose of Sirolimus, demonstrated enhanced efficacy in transplantation tolerance induction in models of skin transplantation and acute Graft-versus-Host disease (GvHD). This data is being presented today in a poster titled “Donor-Specific Tolerance Induction by [...]

May 12th, 2009|

REGiMMUNE Receives $12 Million in Grants to Develop Transplant and Allergy Drugs

Mountain View, CA and TOKYO – December 8, 2008 – REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, today announced that it has received two separate grants totaling more than $12 million from the Japan Science and Technology Agency (JST) and from National Institute of Biomedical Innovation (NIBIO). [...]

December 8th, 2008|

REGiMMUNE to Present at the 50th ASH Annual Meeting

Mountain View, CA – December 5, 2008 – REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, will present preclinical data on the company’s potential therapeutic treatment for Graft versus Host Disease (GvHD) at the American Society of Hematology Annual Meeting (ASH) being held December 6 through 9 in San Francisco, [...]

November 6th, 2008|

NEWS release of “Novel immunotherapy for treatment of cedar allergy”

The release is primarily for Japan but breifly; 1. RIKEN and REGiMMUNE has developed recombinant cedar antigen for treatment of cedar allergy. Because of its unique conformation, it has lower or no risk of anaphylactic shock which is expected for native antige used for desensitization therapy. 2. Animal studies have been conducted and efficacy and [...]

July 31st, 2008|

Relocation of Headquarters in Japan

Japan headquarters has been relocated to following address as of August 1st 2008. 1-7-8 Kaigan Tokyo Industrial Trade Center 607 (6th Floor) Minato-ku Tokyo 105-0022 JAPAN for detailed direction, please see accesss page

July 28th, 2008|